IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar.
An archived replay will be available after the call concludes on Oncocyte’s investor relations website at https://investors.oncocyte.com.
About Oncocyte
Oncocyte is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.oncocyte.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.73 |
| Daily Volume: | 0 |
| Market Cap: | US$45.970M |
November 10, 2025 October 06, 2025 September 24, 2025 September 08, 2025 September 08, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
